Physicians' Academy for Cardiovascular Education
Diabetes type II confers an increased CVD risk. Recent scientific developments have yielded antidiabetic agents that positively impact CV risk in diabetic patients. Follow the latest insights into the close link between diabetes and CVD.
AHA 2018 The American Heart Association (AHA) and the American College of Cardiology (ACC) updated the 2018 cholesterol guidelines. A summary of key recommendations concerning cholesterol management in de prevention of CVD.
AHA 2018 Dapagliflozin was evaluated in both primary and secondary prevention patients with T2DM. Stephen Wiviott summarizes the results of DECLARE TIMI-58, along with those of a meta-analysis of the 3 SGLT2i CVOTs.
AHA 2018 Dapagliflozin was associated with a reduction in CVD/hospitalization in T2DM patients with ASCVD or with multiple risk factors, and with a modest decrease in MACE in those with existing ASCVD.
In this randomized trial, the long-term intensive PREDIMED-Plus lifestyle intervention resulted in weight loss and reduced CV risk in overweight/obese adults with metabolic syndrome, compared to standard care.
The real-world EMPRISE trial showed reduced risk for HF hospitalization with the SGLT2 inhibitor empagliflozin, compared with DPP-4 inhibitors in subjects with T2DM and CVD.
The REWIND study met its primary efficacy endpoint, showing that administration of the GLP-1 RA dulaglutide once-weekly significantly reduces MACE versus placebo in adult diabetic patients with or without CVD.
A retrospective cohort study showed an association between bariatric surgery and lower risk of macrovascular outcomes in T2DM patients with BMI ≥35, compared with matched controls who did not undergo surgery.
This umbrella review of recent systematic reviews and meta-analyses compared the effectiveness and underlying mechanisms of various prevention and treatment strategies to regulate blood glucose.
Download the meeting impression of this PACE symposium during ESC 2018, which reviewed PCSK9 inhibition with regard to science, outcomes and guidance.
In recent years, new insights into the CV risk associated with diabetes have resulted in a new management approach of T2DM. Prof. Deanfield explains the rationale of a multifactorial approach.
In diabetes patients at high CV risk, after a temporary drop in eGFR, empagliflozin significantly slowed eGFR decline compared with placebo, as observed in a prespecified eGFR slope analysis of the EMPA-REG OUTCOME trial.
In a posthoc analysis of the LEADER trial, liraglutide treatment was associated with fewer CV outcomes patients with type 2 diabetes and chronic kidney disease at high CV risk.
